Laboratory Information Systems (LIS): Page 2

Video from AACC: Highlights of Day 3
By Leo O'Connor
We discuss the impressive attendance and exhibits, the adjustments the industry has made for COVID-19, novel assay products, lab staff shortages, and other news from AACC 2022.
July 27, 2022
2022 07 28 21 49 9335 Wrapup 400
Video from AACC: Cloud-connected point-of-care diagnostics
By Leo O'Connor
Click on the video below to watch the interview.
July 27, 2022
2022 07 28 16 29 1805 Adelnman And Wong 400
Video from AACC: BrightInsight's Connected Diagnostics Platform
By Leo O'Connor
Dr. Kal Patel, CEO and co-founder, and Andrea Curtis, director of in vitro diagnostics product management, sat down with ScienceBoard.net's sister site LabPulse.com to discuss how the platform enables greater product innovation, new revenue streams, and streamlined workflows.
July 27, 2022
2022 07 28 15 39 8857 Patel And Curtis 400
Grail, AstraZeneca to collaborate on companion diagnostic tests
By LabPulse.com staff writers
The firms will focus first on developing CDx tests using Grail's methylation platform to identify and recruit patients with high-risk, early-stage cancer for AstraZeneca's clinical studies.
June 1, 2022
2019 08 12 20 23 3708 Lab Blood Centrifuge 400
Agilent secures CE-IVD Mark for cervical cancer test
By LabPulse.com staff writers
PD-L1 is an antibody expressed by cervical cancer tumors and is a key biomarker for predicting response to anti-PD-L1 therapies like Keytruda, according to Agilent. The company's PD-L1 IHC 22C3 pharmDx companion diagnostic identifies cervical cancer patients with a PD-L1 combined positive score of one or more, which indicates that they could benefit from treatment with Keytruda, the company said.
May 10, 2022
2019 11 07 23 47 6944 Squamous Epithelial Cells Cervical 400
Pandemic silver lining: COVID drives digital pathology adoption
By Leah Sherwood
During the presentation, Dr. Liron Pantanowitz, a professor of pathology and the director of anatomic pathology at the University of Michigan, offered a glimpse into the future of pathology -- both at work and in teaching -- once the pandemic has passed.
March 21, 2022
2022 03 21 17 29 0128 Uscap 400
Foundation Medicine nabs FDA clearance for NSLC diagnostic
By LabPulse.com staff writers
The test received FDA clearance in February for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda) treatment. FoundationOne CDx can now also be used as a companion diagnostic to identify patients with NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) alterations.
March 17, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Guardant wins new clearances in Japan for liquid biopsy test
By LabPulse.com staff writers
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
2022 03 08 19 56 8772 Clearance Stamp 400
Labs need to improve functionality, security of LIS
By Melissa Busch
Achieving operational efficiencies throughout the lab is integral for diagnostic providers, requiring an LIS infrastructure that is functional, reliable, interoperable, and highly secure. As the U.S. moves toward an endemic approach to infectious disease, which will continue to drive testing, these survey results highlight significant shortcomings, the company said.
February 27, 2022
2022 02 10 03 12 6159 Computer Data 400
FDA clears Foundation Medicine's companion diagnostic
By LabPulse.com staff writers
Characterizing these tumors helps clinicians identify patients who could benefit from immunotherapy such as Keytruda, a humanized antibody used in cancer immunotherapy, the company said. MSI-H status is a defining feature of colorectal, endometrial, and gastrointestinal cancers.
February 22, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Invitae launches 2 IVD cancer tests in Europe
By LabPulse.com staff writers
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
2022 01 12 21 29 6223 Europe Signpost 400
Digital pathology recovers from COVID setback
By Bruce Carlson
The digital pathology market, which consists of hardware, software, and related services for clinical applications, has largely benefitted from the COVID-19 pandemic, allowing pathologist to read, evaluate, and collaborate remotely, improving efficiency and productivity.
February 2, 2022
2022 02 01 16 04 7322 Digital Pathology Cytology 400
Previous Page
Page 2 of 16
Next Page